Nat Immun:科学家发现动脉硬化治疗新靶点netrin-1

2012-01-20 MedSci MedSci原创

最近,NYU Langone Medical Center的研究人员在2012年1月8日的Nature Immunology杂志上发表的一项新研究"The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques"称,他们发现

最近,NYU Langone Medical Center的研究人员在2012年1月8日的Nature Immunology杂志上发表的一项新研究"The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques"称,他们发现了导致动脉硬化的新的起因。 据NYU Langone医学中心内科和细胞生理专业的助理教授Kathryn J. Moore介绍:“我们已经发现积聚在斑块内的巨噬细胞能分泌一种分子叫做netrin-1,我们的研究显示netrin-1能阻碍巨噬细胞的正常运动,从而引起这些免疫细胞的积聚,加快动脉硬化的进度。” 动脉硬化是由动脉壁内充满胆固醇的巨噬细胞所引起的。正常情况下,免疫系统将巨噬细胞送达到动脉内来清除胆固醇的沉淀,但病理情况下,巨噬细胞就会在动脉内停留,引起人体的炎症反应,巨噬细胞就成为动脉壁内斑块的主要成分。一直到现在,巨噬细胞停留在动脉内的机理还未知。 在这项研究中,研究者揭示了巨噬细胞停

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1802152, encodeId=0c9218021525e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jul 24 11:26:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733586, encodeId=ed551e33586dc, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Apr 25 03:26:00 CST 2012, time=2012-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879117, encodeId=c86a18e911726, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 10 20:26:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288104, encodeId=65ad128810404, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Jan 21 15:26:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517334, encodeId=825c151e3346c, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sat Jan 21 15:26:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1802152, encodeId=0c9218021525e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jul 24 11:26:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733586, encodeId=ed551e33586dc, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Apr 25 03:26:00 CST 2012, time=2012-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879117, encodeId=c86a18e911726, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 10 20:26:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288104, encodeId=65ad128810404, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Jan 21 15:26:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517334, encodeId=825c151e3346c, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sat Jan 21 15:26:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
    2012-04-25 canlab
  3. [GetPortalCommentsPageByObjectIdResponse(id=1802152, encodeId=0c9218021525e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jul 24 11:26:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733586, encodeId=ed551e33586dc, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Apr 25 03:26:00 CST 2012, time=2012-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879117, encodeId=c86a18e911726, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 10 20:26:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288104, encodeId=65ad128810404, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Jan 21 15:26:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517334, encodeId=825c151e3346c, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sat Jan 21 15:26:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
    2012-07-10 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1802152, encodeId=0c9218021525e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jul 24 11:26:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733586, encodeId=ed551e33586dc, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Apr 25 03:26:00 CST 2012, time=2012-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879117, encodeId=c86a18e911726, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 10 20:26:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288104, encodeId=65ad128810404, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Jan 21 15:26:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517334, encodeId=825c151e3346c, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sat Jan 21 15:26:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1802152, encodeId=0c9218021525e, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jul 24 11:26:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733586, encodeId=ed551e33586dc, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Apr 25 03:26:00 CST 2012, time=2012-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879117, encodeId=c86a18e911726, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 10 20:26:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288104, encodeId=65ad128810404, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Jan 21 15:26:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517334, encodeId=825c151e3346c, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sat Jan 21 15:26:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]